CD47 and neoplasm: Xie et al. generated VHH-based CAR-T cells, which were designed to target PD-L1, CD47, or EIIIB+ fibronectin splice variant to target the TME, and each VHH-based CAR-T could reduce solid tumor growth and improve survival in immunocompetent tumor-bearing mice [160,161].